The “Elavay: Patient Insights. Elevated Healthcare. Diabetes Report” reveals key findings and outstanding achievements from top companies in the industry (on a 7-point Likert scale):

• Sanofi excels in Policy Support, leading with an impressive average rating of 4.85. Their commitment is further demonstrated through high scores in Advisory Initiatives (6.83) and Coalition Support (6.50), showcasing their strategic guidance and robust engagement with patient advocacy groups.
• Eli Lilly leads in Corporate Image & Reputation with the highest average rating of 6.25 and an 80% response rate. Their dedication to advancing healthcare through Conferences, Meetings & Symposia (6.38) and Patient-Centric Insights & Collaboration (6.14) reflects a strong patient-focused approach.
• Dexcom is recognized for its innovation and leadership in expanding access and education for diabetes treatments (5.86). They achieve top ratings in Coalition Support (6.43) and Advisory Initiatives (6.50), emphasizing their proactive role in enhancing patient care and disease management. When we remove evaluating the efforts in Social Determinants of Health & Health Equity, Dexcom actually takes the lead from Sanofi & Eli Lilly in diabetes care.
• Novo Nordisk, while facing some challenges as its business shifts to cardiometabolic disease, continues to make significant contributions in Corporate Image & Reputation and Disease Education & Awareness, highlighting their ongoing efforts to support the diabetes community.